semaglutide and cardiovascular outcomes in patients with type 2 diabetes Trial (CVOT) SOUL (Semaglutide cardiOvascular oUtcomes triaL)

Results Of the 138,397 patients, 57% received neither SGLT2-I nor GLP-1RA, 17% received both, 20% received SGLT2-I only, and 6% received GLP-1RA only

Third-party tested purity

Methods PIONEER REAL Switzerland was a 3444-week, multicentre, prospective, non-interventional, single-arm study of adults with T2D nave to injectable glucose-lowering medication who were initiated on oral semaglutide in routine clinical practice

That includes treatment of cardiovascular and bone pathologies, cutaneous ulcers, organ transplantation and pancreatic beta-cell regeneration, among others

It's normal to have questions

3 (6.1%) required a phone call